Results 231 to 240 of about 147,468 (308)

<i>Lycium barbarum</i> polysaccharides as prebiotics prevent colorectal cancer liver metastasis in non-alcoholic fatty liver disease by modulating gut microbiota-<i>FGF21-PI3K-AKT</i> axis. [PDF]

Front Pharmacol
Zhao S, Tan Z, Suo J, Bu Y.
europepmc   +1 more source

Clinical Conditions Associated With a High Antinuclear Antibody Titer in Individuals Without Autoimmune Disease

Arthritis Care &Research, Volume 78, Issue 5, Page 662-669, May 2026.
Objective Antinuclear antibodies (ANAs) are present at high titers in 2% of the general population, but their clinical significance in individuals without an autoimmune (AI) disease is not known. We tested the hypothesis that the presence of a high ANA titer in non‐AI conditions is associated with disease.
Matthew Chung, John P. Shelley, Gul Karakoc, John Still, Xiaodi Ruan, Jonathan Mosley, C. Michael Stein, Vivian K. Kawai   +7 more
wiley   +1 more source

Hepatokines and polycystic ovary syndrome: investigating the connection between the hepato-ovarian axis and disorders in glycolipid metabolism in PCOS: a narrative review. [PDF]

Front Endocrinol (Lausanne)
Zhu R, Wang X, Ma J, Shi X, Zhang Y, Jin J, Zhou H.   +6 more
europepmc   +1 more source

GLP‐1 agonists and the gut microbiome: A bidirectional relationship

British Journal of Clinical Pharmacology, Volume 92, Issue 5, Page 1309-1325, May 2026.
Abstract Glucagon‐like peptide‐1 (GLP‐1) receptor agonists have transformed the management of type 2 diabetes mellitus (T2DM) and obesity, yet their interactions with the gut microbiome remain an emerging frontier in pharmacological and metabolic research.
Srinivas Kamath, Nicole S. L. Chan, Paul Joyce   +2 more
wiley   +1 more source

Meta-Analysis of Genetic Variants Associated With HBV Infection Susceptibility and Hepatocellular Carcinoma Risk. [PDF]

J Viral Hepat
Lee SY, Shin HD.
europepmc   +1 more source

Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD‐1 Inhibitors in Advanced Hepatocellular Carcinoma

Cancer Medicine, Volume 15, Issue 5, May 2026.
ABSTRACT Background and Aims This study aimed to explore the predictive value of intratumoral proton density fat fraction (PDFF) and the clinical efficacy of hepatic arterial infusion chemotherapy (HAIC) combined with anti‐programmed cell death protein 1 (anti‐PD‐1) therapy in advanced hepatocellular carcinoma (HCC).
Yujie Ye, Yunzheng Li, Yanjun Lu, Yanchao Xu, Laizhu Zhang, Yican Zhu, Huan Li, Binghua Li, Min Zhou, Decai Yu   +9 more
wiley   +1 more source

Integrative Network Pharmacology, Molecular Docking, and In Vitro Insights Into the Mechanism of Finger Citron for Non-Alcoholic Fatty Liver Disease. [PDF]

Food Sci Nutr
Li Q, Sun H, Chen X, Chen C, Chen Y, He H, Yang F, Wang D, Zhou L.   +8 more
europepmc   +1 more source

Gut Dysbiosis as a Shared Mechanism in Obesity and Hypertension: Exploring a Promising Therapeutic Avenue

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This review synthesises current knowledge on gut microbiome involvement in obesity and hypertension, evaluates microbiome‐based therapeutic strategies, and identifies critical research gaps to guide future investigations aimed at mitigating the dual pandemics.
Andrej Belančić, Almir Fajkić, Yusuf Ziya Sener, Ana Jelaković, Lejla Alić, Elvira Meni Maria Gkrinia, Donatella Verbanac, Bojan Jelaković   +7 more
wiley   +1 more source

Adipose Tissue and Lipid Dysregulation Contributions to Cachexia, Sarcopenia and Muscle Function

Journal of Cachexia, Sarcopenia and Muscle, Volume 17, Issue 3, June 2026.
Joseph D. Abraham, Stephan von Haehling, Stefan D. Anker   +2 more
wiley   +1 more source

Comparative Efficacy and Safety of Resmetirom and Efruxifermin for Metabolic Dysfunction‐Associated Steatohepatitis: A Network Meta‐Analysis of Randomized Controlled Trials

Endocrinology, Diabetes &Metabolism, Volume 9, Issue 3, May 2026.
This meta‐analysis compared Resmetirom and Efruxifermin in patients with MASH, focusing on improvements in key biochemical and non‐invasive markers. Efruxifermin is associated with favourable outcomes with a slightly greater effect on MRI‐PDFF and AST, along with more comparable safety outcomes.
Doha Jaber, Inas Jaber, Ayah Abu Lehia, Thekrayat Asad, Hazem Ayesh   +4 more
wiley   +1 more source